Caprius - Turn Around Spekulation - 500 Beiträge pro Seite

[V51]

US Symbol CAPR
WKN 910514

Das Geschäft von Caprius liegt in 2 Bereichen:

1.) Sie verkaufen über eine Handelsgesellschaft 14 verschiedene medizinische Diagnosegeräte

2.) Sie betreiben das "Strax Institute", eine ultramoderne Krebsvorsorgeklinik in Lauderhill, Florida. Unter anderem werden in der Klinik auch 3 Hightech-Mammographiegeräte eingesetzt. Aus der Entwicklung und dem Vertrieb dieser Geräte ist Caprius hervorgegangen.

Als die Firma 1999 von der Forschungs- und Entwicklungsgesellschaft, die sie mal waren, in das Vertriebsstadium treten wollte, hat sie das wohl fast dahingerafft. Delisting war die Folge. Caprius wurde daraufhin umstrukturiert. Erster Schritt war das eigene Betreiben der Kliniken, die die Caprius-Geräte einsetzen. Zusätzlich wurde auch das Vertriebsgeschäft gestärkt.

Mit den Finanzen sieht es bei Caprius inzwischen wieder ganz ok aus. Wie öfter stimmen wohl die Infos bei Yahoo nicht, der Quartalsbericht sagt auf jeden Fall etwas anderes. Danach müßte die Firma aus einer Zwischenfinanzierung im Juni 300.000$ erhalten haben. Die Finanzierung wurde von den Dirketoren der Firma übernommen(!!), das ist schonmal kein schlechtes Zeichen. Wenn die diese Finanzierung wirklich übernommen haben, weil Caprius bald den break even erreicht, wäre das natürlich der Hammer. Nah dran sind sie ohnehin schon, im letzten Quartal fielen noch ganzen -246.000$ an.

Die zweite Möglichkeit wäre, daß jetzt nach der Konsolidierung der Firma die Weiterentwicklung der wohl führenden Diagnosegeräte zur Früherkennung von Brustkrebs wieder verstärkt vorangetrieben wird. Auf jeden Fall haben sie nach Aussage des letzten Quartalsberichts die Forschungsaktivitäten auch wieder aufgenommen.

Ich bin auf die gestoßen, weil da immer mal ein paar auch mal in Deutschland gehandelt werden. Medizintechnik ist ohnehin ein Bereich, in dem ich investieren mag. Das ist zwar fast schon makaber, daß Brustkrebs-Früherkennung Konjunktur hat, aber ist ja nun mal so.

Naja mal schauen, das Potential nach unten ist bei dem Kurs ja doch sehr begrenzt, *g*.

[ajuga]

Toll, dass sich jemand mit Caprius beschäftigt!

Die kenne ich noch von früher! Habe Caprius sogar mal im Depot gehabt. Advanced NMR Systems haben mir vor Jahren auch ein paar Gewinne eingebracht (Zockerei). Caprius ist aus einer Fusion der Unternehmen Advanced Mammography Systems und Advanced NMR Systems hervorgegangen.

Ich werde CAPR auch wieder auf meine Beobachtungsliste nehmen.


ajuga
http://www.usmusterdepot.de/

[ajuga]

Also die letzten Finanzdaten, die ich gefunden habe, sind vom 30.06.2001.
Das letzte ordentliche News-Release vom 06.12.00!
Ist irgendwie nicht sehr überzeugend!


Der Wert wird allerdings sogar in Deutschland relativ aktiv gehandelt.

Aber zum jetzigen Zeitpunkt ist das alles Zockerei. Es ist abzuwarten ob überhaupt nocheinmal Quartalsberichte oder News veröffentlicht werden oder endlich der Webauftritt auf www.caprius.com startet.

[onlythebest]

@all
Keine Panik caprius wird eher übernomment ( Abbott)
als dass Sie Pleite gehen
meine Anfrage vom Dezember zum Jahresabschlusstermin :
Dear Mrxxxxx,

Thank you for your email. Please be advised that we are working on our year
end reports and will file a 10 K in the early new year for fiscal year ended
September 30, 2001.

To answer your question regarding our webpage for Opus Diagnostics, we were
having difficulties with our provider and will resolve the problems in the
near future.

Sincerely,

Mrs. Beverly Tkaczenko

******************************************
Beverly Tkaczenko
Director, Corporate Communications
Caprius, Inc.
One Parker Plaza
Fort Lee, NJ 07024
Phone: [phone]
Fax: [phone]

[onlythebest]

Hier haben wir doch den Jahreabschlussreport...
interessant wird der nächste Quartalsbericht
gruss onlythebest


CAPRIUS INC (CAPR.OB)
Annual Report (SEC form 10KSB)
ITEM 6. MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS


MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF

OPERATIONS


The following discussion should be read in conjunction with the audited consolidated financial statements and notes thereto for the years ended September 30, 2001 and 2000.




RESULTS OF OPERATIONS


Fiscal Year Ended September 30, 2001 Compared to Fiscal Year Ended September 30, 2000

Included in revenues for Fiscal 2001 are $2,043,000 of net sales revenues for Opus therapeutic drug monitoring assays versus $1,920,000 for Fiscal 2000. The cost of operations for the Opus business for Fiscal 2001 was $715,000 versus $620,000 for the prior year. While reagent kit unit sales increased by 23.6% in Fiscal 2001 versus Fiscal 2000, aggregate net product sales revenues were impacted due to the change effective October 1, 2000 to an exclusive distributor for the United States. Sales prices are significantly lower when selling through a distributor as opposed to selling directly to end user customers.

Net patient service revenue at Strax totaled $ 1,503,000 for the year ended September 30, 2001 ("Fiscal 2001") versus $1,479,000 for the year ended September 30, 2000 ("Fiscal 2000"). Cost of service operations totaled $1,077,000 for Fiscal 2001 versus $965,000 for Fiscal 2000. The increases from Fiscal 2000 to Fiscal 2001 reflect the efforts at Strax to add higher paying and more costly procedures at a time when reimbursement rates are being heavily negotiated by the healthcare providers and expenses continue to rise.

Selling, general and administrative expenses totaled $1,822,000 for Fiscal 2001 versus $2,628,000 for Fiscal 2000. This decrease reflects the Company`s continued efforts to reduce corporate overhead and also reflects one time severance, directors fees and expense payments that were made to two former executive officers aggregating approximately $564,000 that were paid in Fiscal 2000.

Based on current market conditions and an analysis of projected undiscounted future cash flows calculated, the Company has determined that the carrying amount of certain long-lived assets of the Strax Institute may not be recoverable. The resultant impairment of long-lived assets has necessitated a write-down of $500,000 of goodwill, which represents the excess of cost over the net assets acquired of the Strax Institute.

Research and development expenses totaled $187,000 for Fiscal 2001 versus $16,000 for Fiscal 2000. This increase reflects the increasing expenditures on the Company`s projects under development for new therapeutic drug monitoring tests.

The operating loss from operations totaled $778,000 for Fiscal 2001 versus $833,000 for Fiscal 2000. This decrease reflects the shift in business operations to the more profitable Opus therapeutic drug monitoring business. The loss for Fiscal 2001 includes a write-down of goodwill of $500,000 reflecting the impairment in value of the Strax Institute, for which there was no comparative expense in Fiscal 2000. Excluding this charge, the operating loss for Fiscal 2001 would have totaled $278,000 versus $833,000 for Fiscal 2000.

Included in interest expense for Fiscal 2001 was $7,000 which represented a non-cash charge for the discount on the Bridge Loans which were issued during the year. Included in interest expense for Fiscal 2000 was $227,000 which represented a non-cash charge for the discount on the Bridge Loans which were issued and repaid during that year.


LIQUIDITY AND CAPITAL RESOURCES


During February and March 2001, the Company completed a short term bridge loan of $300,000 through the issuance of loan notes due on February 28, 2002 together with warrants, the proceeds of which were used principally for working capital and purchase of raw materials previously owned by Oxis, the previous manufacturer and owner of the Opus products.

In March and April 2000, the Company completed an equity private placement of $1,950,000 through the sale of 650,000 units at $3.00 per unit as described in Note H-3 to the Financial Statements. The Company utilized the net funds for the repayments mentioned below and the balance was used for working capital purposes to continue developing the business of Opus by adding new distributors in territories currently not covered by existing distributors and for the




development of new diagnostic kits and the acquisition of additional product lines. The Company has been attempting to sell Strax. The $300,000 short term bridge loan notes are secured by the assets of Strax and are due for repayment on February 28, 2002. The Company continues to pursue efforts to identify additional funds through various funding options, including banking facilities, government-funded grants and equity offerings in order to provide capital for future expansion. The ability to secure equity financing has been more difficult due to the Company`s June 1999 delisting from the NASDAQ Small Cap System. There can be no assurance that such funding initiatives will be successful, and in light of the current low market price any equity placement would result in substantial dilution to current stockholders. Consequently, the Company`s viability could be threatened. Accordingly, the auditors` report on the 2001 financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.

Net cash used in operations for the year ended Fiscal 2001 amounted to $440,000. There were no significant cash flows used in investing activities for Fiscal 2001. Cash flows from financing activities in Fiscal 2001 decreased from Fiscal 2000 due to the proceeds from the sale of Common Stock in 2000.


RECENT ACCOUNTING PRONOUNCEMENTS


In June 2001, the Financial Accounting Standards Board finalized FASB Statements No. 141, Business Combinations ("SFAS 141"), and No. 142, Goodwill and Other Intangible Assets ("SFAS 142"). SFAS 141 requires the use of the purchase method of accounting and prohibits the use of the pooling-of-interests method of accounting for business combinations initiated after June 30, 2001. SFAS 141 also requires that the Company recognize acquired intangible assets apart from goodwill if the acquired intangible assets meet certain criteria. SFAS 141 applies to all business combinations initiated after June 30, 2001 and for purchase business combinations completed on or after July 1, 2001. It also requires, upon adoption of SFAS 142, that the Company reclassify the carrying amounts of intangible assets and goodwill based on the criteria in SFAS 141.

SFAS 142 requires, among other things, that companies no longer amortize goodwill, but instead test goodwill for impairment at least annually. In addition, SFAS 142 requires that the Company identify reporting units for the purposes of assessing potential future impairments of goodwill, reassess the useful lives of other existing recognized intangible assets, and cease amortization of intangible assets with an indefinite useful life. An intangible asset with an indefinite useful life should be tested for impairment in accordance with the guidance in SFAS 142. SFAS 142 is required to be applied in fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized at that date, regardless of when those assets were initially recognized. The Company expects to adopt SFAS in the first quarter of fiscal 2003. SFAS 142 requires the Company to complete a transitional goodwill impairment test by six months from date of adoption. The Company is also required to reassess the useful lives of other intangible assets within the first interim quarter after adoption 0f SFAS 142.

The Company`s previous business combinations were accounted for using the purchase method, the net carrying amount of goodwill related to those combinations was $928,671 and other intangible assets was $1,296,081 at September 30, 2001. Amortization expense for the year ended September 30, 2001 was $155,459. The Company is assessing but has not yet determined how the adoption of SFAS 141 and SFAS 142 will effect its future financial position and results of operations.

In October 2001, the FASB issued SFAS 144, "Accounting for the Impairment of Disposal of Long-Lived Assets," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This Statement supersedes SFAS 121, "Accounting for the Impairment of Long-Lived Assets to be Disposed Of," and APB Opinion No. 30, "Reporting the Results of Operations -Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions for the Disposal of a Segment of a Business." SFAS 144 becomes effective for the fiscal years beginning after December 15, 2001. The Company expects to adopt SFAS 144 in the first quarter of fiscal 2003 and is currently reviewing the effects of adopting SFAS 144 on its financial position and results of operations.





FORWARD LOOKING STATEMENTS


The Company is including the following cautionary statement in this Annual Report of Form 10-KSB to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein are forward-looking statements and accordingly involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company`s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitation, management`s examination of historical operating trends, data contained in the Company`s records and other data available from third parties, but there can be no assurance that management`s expectation, beliefs or projections will result or be achieved or accomplished. In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward-looking statements: technological advances by the Company`s competitors, changes in health care reform, including reimbursement programs, capital needs to fund any delays or extensions of development programs, delays in new product development, delays in obtaining regulatory clearance for new products, changes in governmental regulations, and availability of capital on terms satisfactory to the Company. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

[Ischlich]

es tut sich mal wieder was bei caprius, weiß jemand mehr?